BIO-TECHNE CORP shareholders Q2 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Blue Water Life Science Advisors, LP 46,500$16,119,0008.75%
Montanaro Asset Management Ltd 93,950$32,567,0004.90%
Jackson Square Partners, LLC 556,157$192,786,0004.50%
STONE RUN CAPITAL, LLC 22,405$7,767,0003.91%
Ownership Capital B.V. 655,654$227,276,0003.90%
Brown Capital Management 839,587$291,034,0003.90%
Sandhill Capital Partners LLC 97,382$33,757,0003.61%
DF DENT & CO INC 684,026$237,111,0003.34%
Spence Asset Management 27,946$9,687,0003.17%
MAIRS & POWER INC 655,930$227,371,0002.72%
Pembroke Management, LTD 75,804$26,276,0002.72%
Summit Creek Advisors LLC 58,142$20,154,0002.57%
AMERICAN CAPITAL MANAGEMENT INC 193,480$67,068,0002.51%
Aristotle Atlantic Partners, LLC 93,267$32,330,0002.49%
Standard Family Office LLC 708$245,0002.43%
GENEVA CAPITAL MANAGEMENT LLC 256,177$88,801,0002.04%
BAMCO INC /NY/ 1,451,376$503,105,0001.62%
Select Equity Group, L.P. 1,321,431$458,061,0001.47%
Winslow Capital Management, LLC 1,550,198$537,360,0001.44%
Affiance Financial, LLC 6,258$2,169,0001.17%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.